Patents Assigned to PCI Biotech AS
  • Patent number: 10166401
    Abstract: A device for activating light-induced rupture of endocytic vesicles in target cells of a patient so as to effect delivery of an administered antigen to cytosol in the target cells, is described. The device is adapted to be worn by a patient over a region of skin where an antigen and a photosensitising agent are to be administered. The device comprises a rear surface that is rounded or otherwise configured to be worn against the patient's skin. It has a retaining part for retaining the device in place over the region of the patient's skin during an activation cycle. A light source is arranged to illuminate the patient's skin from the rear of the device. A control system is configured to vary the output of the light source with respect to time in accordance with a pre-configured output sequence.
    Type: Grant
    Filed: August 28, 2014
    Date of Patent: January 1, 2019
    Assignee: PCI BIOTECH AS
    Inventors: Anders Hogset, Per Edvard Walday, Kristin Eivindvik
  • Patent number: 9901636
    Abstract: The present invention relates to novel chitosan-based conjugates, e.g. nanocarriers, comprising a derivative of the biocompatible polymer chitosan conjugated to a photosensitizing agent, and uses thereof in photochemical internalization (PCI) and photodynamic therapy (PDT). The invention also relates to the use of the novel conjugates of the invention in treatment or prevention of diseases, particularly cancer, and for vaccination purposes.
    Type: Grant
    Filed: May 14, 2013
    Date of Patent: February 27, 2018
    Assignee: PCI BIOTECH AS
    Inventors: Kristian Berg, Anders Hogset, Mar Masson, Vivek S. Gaware
  • Publication number: 20180050105
    Abstract: The invention concerns a method of generating an immune response in a subject, comprising administering to the subject an antigenic molecule, a photosensitizing agent, a checkpoint inhibitor, and irradiating said subject with light of a wavelength effective to activate the photosensitizing agent to generate an immune response. Preferably the method is a method of vaccination. The invention also provides related methods, compositions, cells, uses, products and kits.
    Type: Application
    Filed: March 4, 2016
    Publication date: February 22, 2018
    Applicant: PCI Biotech AS
    Inventor: Anders HØGSET
  • Publication number: 20170252441
    Abstract: The present invention provides a method of expressing an antigenic molecule or a part thereof on the surface of a cell using a photochemical internalisation method in which a cytokine, preferably GM-CSF, is used to enhance the method. The method may be used to stimulate an immune response and for various therapeutic or prophylactic methods. Pharmaceutical compositions or kits comprising the components for use in the method, cells produced by the method and their use in therapy and prophylaxis also form aspects of the invention.
    Type: Application
    Filed: August 28, 2015
    Publication date: September 7, 2017
    Applicant: PCI Biotech AS
    Inventors: Anders HØGSET, Pål JOHANSEN
  • Patent number: 9737594
    Abstract: The present invention provides a method of stimulating an immune response to an antigenic molecule, by contacting a cell with the antigenic molecule and with a photosensitizing agent, irradiating the cell, and thereby presenting the antigenic molecule, or part thereof, on the surface of said cell and stimulating an immune response.
    Type: Grant
    Filed: July 5, 2012
    Date of Patent: August 22, 2017
    Assignee: PCI Biotech AS
    Inventors: Kristian Berg, Torunn E. Tjelle, Anders Hogset, Lina Prasmickaite
  • Patent number: 9700622
    Abstract: The present invention relates to a method for introducing an siRNA molecule into the cytosol of a cell, said method comprising i) contacting said cell with an siRNA molecule, a carrier and a photosensitizing agent, and ii) irradiating the cell with light of a wavelength effective to activate the photosensitizing agent, wherein said carrier comprises a cationic polyamine such as a lipopolyamine in a non-liposomal formulation, polyethyleneimine (PEI), a betacyclodextrin amine polymer, an amine group containing dendrimer, and a cationic peptide. Cells or a population of cells obtainable by the method, a composition containing an siRNA molecule and the carrier molecule, kits and therapeutic uses of the above are also provided.
    Type: Grant
    Filed: January 12, 2012
    Date of Patent: July 11, 2017
    Assignee: PCI BIOTECH AS
    Inventors: Sigurd Bøe, Eivind Johannes Hovig
  • Publication number: 20170143811
    Abstract: The present invention relates to a method of treating or preventing melanoma using vaccination or immunisation, wherein said vaccination or immunisation involves the use of a photosensitizing agent, a melanoma antigen (i.e. an antigenic molecule), for example a vaccine component, and irradiation with light of a wavelength effective to activate the photosensitizing agent. The invention also relates to said photosensitizing agent and melanoma antigen for use in such a method, and to cells produced by the method.
    Type: Application
    Filed: November 21, 2014
    Publication date: May 25, 2017
    Applicant: PCI Biotech AS
    Inventors: Anders HØGSET, Pål JOHANSEN
  • Publication number: 20160206725
    Abstract: A method of vaccination or immunisation involving the use of a photosensitizing agent, an antigenic molecule, e.g. a vaccine component, and an agent which enhances the effect of photochemical internalization (PCI)-mediated vaccination is disclosed wherein the agent is a ligand for a Toll-like receptor (TLR), and irradiation is with light of a wavelength effective to activate the photosensitizing agent. Antigenic, e.g. vaccine compositions, useful in such a method are also disclosed along with a method of generating antigen presenting cells which may be used to generate an immune response based on introducing antigenic molecules, e.g. vaccine components, into cells to achieve antigen presentation. The invention also provides methods of achieving vaccination in a subject using such cells.
    Type: Application
    Filed: August 28, 2014
    Publication date: July 21, 2016
    Applicant: PCI Biotech AS
    Inventors: Anders HOGSET, Pal JOHANSEN
  • Publication number: 20160199664
    Abstract: A device for activating light-induced rupture of endocytic vesicles in target cells of a patient so as to effect delivery of an administered antigen to cytosol in the target cells, is described. The device is adapted to be worn by a patient over a region of skin where an antigen and a photosensitising agent are to be administered. The device comprises a rear surface that is rounded or otherwise configured to be worn against the patient's skin. It has a retaining part for retaining the device in place over the region of the patient's skin during an activation cycle. A light source is arranged to illuminate the patient's skin from the rear of the device. A control system is configured to vary the output of the light source with respect to time in accordance with a pre-configured output sequence.
    Type: Application
    Filed: August 28, 2014
    Publication date: July 14, 2016
    Applicant: PCI Biotech AS
    Inventors: Anders HOGSET, Per Edvard WALDAY, Kristin EIVINDVIK
  • Publication number: 20160040128
    Abstract: The present invention provides an in vitro method of expressing an antigenic molecule or a part thereof on the surface of a dendritic cell using a PCI method with TPCS2a at a concentration of 0.020-0.1 ?g/ml, using light of a wavelength of between 400 and 500 nm. Methods of treatment such as vaccination comprising this method, together with compositions comprising said cells and uses involving said cells expressing antigenic molecules are also provided.
    Type: Application
    Filed: March 15, 2013
    Publication date: February 11, 2016
    Applicant: PCI BIOTECH AS
    Inventors: Pål JOHANSEN, Anders HØGSET
  • Patent number: 9241996
    Abstract: The present invention relates to a method for enhancing the activity of kinase inhibitors in target cells, and more specifically for enhancing the activity of tyrosine kinase inhibitors (TKIs), said method comprising contacting a cell with a kinase inhibitor and a photosensitizing agent and irradiating said cell with light of a wavelength effective to activate the photosensitizing agent, and to the use of this method for enhancing the effects of kinase inhibitors or kinase inhibitor-based drugs in particular to achieve cell death, for example, in cancer treatment and other diseases or conditions in which kinase inhibitors, such as TKIs, have a beneficial effect.
    Type: Grant
    Filed: June 26, 2009
    Date of Patent: January 26, 2016
    Assignee: PCI BIOTECH AS
    Inventors: Anders Høgset, Anette Weyergang, P{dot over (a)}l Kristian Selbo, Kristian Berg
  • Publication number: 20150202293
    Abstract: The present invention relates to novel chitosan-based conjugates, e.g. nanocarriers, comprising a derivative of the biocompatible polymer chitosan conjugated to a photosensitising agent, and uses thereof in photochemical internalisation (PCI) and photodynamic therapy (PDT). The invention also relates to the use of the novel conjugates of the invention in treatment or prevention of diseases, particularly cancer, and for vaccination purposes.
    Type: Application
    Filed: May 14, 2013
    Publication date: July 23, 2015
    Applicant: PCI BIOTECH AS
    Inventors: Kristian Berg, Anders Hogset, Mar Masson, Vivek S. Gaware
  • Patent number: 9026203
    Abstract: The invention relates to pharmaceutically acceptable salts of amphiphilic photosensitizing agents which have a water solubility of at least 0.5 mg/ml and to their use in methods of photochemical internalization. Such salts may be formed from a pharmaceutically acceptable base, for example an organic amine such as an amino alcohol, or from a pharmaceutically acceptable acid, for example a sulphonic acid or a sulphonic acid derivative. Due to their increased water solubility, such salts are particularly suitable for use in the preparation of parenteral pharmaceutical preparations, e.g. for use as solutions for injection or infusion.
    Type: Grant
    Filed: August 16, 2010
    Date of Patent: May 5, 2015
    Assignee: PCI Biotech AS
    Inventors: Jo Klaveness, Anders Hogset
  • Publication number: 20130330363
    Abstract: The present invention provides a method of expressing an antigenic molecule or a part thereof on the surface of an antigen-presenting cell, said method comprising introducing a molecule into the cell cytosol by photochemical internalisation, wherein said molecule, or a part thereof, is subsequently presented on the surface of said cell. Methods of vaccination comprising this method, together with compositions comprising said cells and uses involving said cells expressing antigenic molecules are also provided.
    Type: Application
    Filed: July 5, 2012
    Publication date: December 12, 2013
    Applicant: PCI Biotech AS
    Inventors: Kristian Berg, Torunn E. Tjelle, Anders Hogset, Lina Prasmickaite
  • Publication number: 20120264807
    Abstract: The present invention relates to a method for introducing an siRNA molecule into the cytosol of a cell, said method comprising i) contacting said cell with an siRNA molecule, a carrier and a photosensitising agent, and ii) irradiating the cell with light of a wavelength effective to activate the photosensitising agent, wherein said carrier comprises a cationic polyamine such as a lipopolyamine in a non-liposomal formulation, polyethyleneimine (PEI), a betacyclodextrin amine polymer, an amine group containing dendrimer, and a cationic peptide. Cells or a population of cells obtainable by the method, a composition containing an siRNA molecule and the carrier molecule, kits and therapeutic uses of the above are also provided.
    Type: Application
    Filed: January 12, 2012
    Publication date: October 18, 2012
    Applicant: PCI BIOTECH AS
    Inventors: Sigurd Bøe, Eivind Johannes Hovig
  • Patent number: 8216587
    Abstract: The present invention provides a method of expressing an antigenic molecule or a part thereof on the surface of an antigen-presenting cell, said method comprising introducing a molecule into the cell cytosol by photochemical internalisation, wherein said molecule, or a part thereof, is subsequently presented on the surface of said cell. Methods of vaccination comprising this method, together with compositions comprising said cells and uses involving said cells expressing antigenic molecules are also provided.
    Type: Grant
    Filed: March 10, 2000
    Date of Patent: July 10, 2012
    Assignee: PCI Biotech AS
    Inventors: Kristian Berg, Torunn E. Tjelle, Anders H øgset, Lina Prasmickaite
  • Patent number: 8096419
    Abstract: The present invention provides photosensitizing agents obtained by reducing a single double bond in the porphyrin macrocycle of a sulphonated meso-tetraphenylporphyrin, preferably a disulphonated meso-tetraphenylporphyrin such as TPPS2a. The resulting sulphonated meso-tetraphenyl chlorins include compounds of formula I: (wherein X is —SO3H; n, p, q and r are each independently 0 or 1; and the sum of n, p, q and r is an integer from 1 to 4, preferably at least 2, e.g. 2 or 4) isomers and isomer mixtures thereof. The compounds of the invention and their pharmaceutically acceptable salts find particular use as photosensitizing agents in the photochemical internalization of molecules and in photodynamic therapy.
    Type: Grant
    Filed: January 19, 2010
    Date of Patent: January 17, 2012
    Assignee: PCI Biotech AS
    Inventors: Claude Rimington, Greta Rimington, legal representative, Kristian Berg, Diem Thuy Thi Tran, Pal Kristian Selbo
  • Publication number: 20110293575
    Abstract: The present invention relates to a method for enhancing the activity of kinase inhibitors in target cells, and more specifically for enhancing the activity of tyrosine kinase inhibitors (TKIs), said method comprising contacting a cell with a kinase inhibitor and a photosensitizing agent and irradiating said cell with light of a wavelength effective to activate the photosensitizing agent, and to the use of this method for enhancing the effects of kinase inhibitors or kinase inhibitor-based drugs in particular to achieve cell death, for example, in cancer treatment and other diseases or conditions in which kinase inhibitors, such as TKIs, have a beneficial effect.
    Type: Application
    Filed: June 26, 2009
    Publication date: December 1, 2011
    Applicant: PCI BIOTECH AS
    Inventors: Anders Høgset, Anette Weyergang, Pål Kristian Selbo, Kristian Berg
  • Patent number: 8008077
    Abstract: The present invention provides a method for introducing a molecule into the cytosol of a cell in which the cell is contacted with a photosensitising agent, the cell is irradiated with light of a wavelength effective to activate the photosensitising agent and, substantially at the same time or after the irradiation, the cell is contacted with the molecule to be introduced, particularly for use in cancer treatment, gene therapy and vaccination.
    Type: Grant
    Filed: May 9, 2007
    Date of Patent: August 30, 2011
    Assignee: PCI Biotech AS
    Inventors: Kristian Berg, Lina Prasmickaite, Anders Hogset, Pal Kristian Selbo
  • Publication number: 20110171184
    Abstract: The present application relates to a method for introducing a PNA molecule into the cytosol, preferably the nucleus of a cell, comprising contacting said cell with a PNA molecule and a photosensitising agent, and irradiating the cell with light of a wavelength effective to activate the photosensitising agent, wherein said PNA molecule is conjugated to a positively charged peptide. Compositions comprising such conjugated PNA molecules, cells made using the method and uses of the method are also described.
    Type: Application
    Filed: July 7, 2005
    Publication date: July 14, 2011
    Applicant: PCI Biotech AS
    Inventors: Eivind Hovig, Oystein Fodstad, Sigurd Boe